αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib
Open Access
- 15 February 2021
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 9 (2), e001162
- https://doi.org/10.1136/jitc-2020-001162
Abstract
Epithelial ovarian cancer (EOC) is the leading cause of death among gynecological malignancies in China. In particular, advanced/refractory ovarian cancer lacks effective targeted therapies due to the immunosuppressive and proangiogenic tumor microenvironment. Mesothelin (MSLN) has been found to be highly expressive in most EOC. Targeting MSLN by antibodies or chimeric antigen receptor-modified T (CAR-T) cells and immune checkpoint blockades as well as apatinib, an anti-angiogenic drug, have been used in patients with refractory ovarian cancer. Apatinib was reported to promote the infiltration of CD8+ T cells in lung cancer. However, the combination therapy of CAR-T secreting anti-PD-1 antibody with apatinib in EOC has not been reported. Case presentation Here we report a case of refractory EOC in a patient who had relapsed after multiline chemotherapy. The patient received autologous T cells that contained sequences encoding single-chain variable fragments specific for MSLN and full-length antibody for PD-1 (αPD-1). The modified T cells were called αPD-1-mesoCAR-T cells. After infusion, the copy number and PD-1 antibody secretion of the CAR-T cells were increased in the blood. By application of multimodality tumor tracking, MRI of the liver showed shrinkage of metastatic nodules from average diameter of 71.3–39.1 mm at month 2. The patient achieved partial response and survived more than 17 months. IL-6 levels in the patient fluctuated from the baseline to 2–4-folds after treatment, but side effects were mild with only grade 1 hypertension and fatigue. Conclusion αPD-1-mesoCAR-T cell therapy combined with apatinib demonstrates a potential therapeutic effect on advanced refractory ovarian cancer. Trial registration number NCT03615313.Funding Information
- Shanghai Cell Therapy Group Corporation (BZ1903)
- Major National Science and Technology Projects, China (2018ZX10302207-003; 2019YFC1316202)
This publication has 26 references indexed in Scilit:
- Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor–Modified T Cells Engineered to Secrete Checkpoint InhibitorsClinical Cancer Research, 2017
- Phosphatase Wip1 in Immunity: An Overview and UpdateFrontiers in Immunology, 2017
- CAR T Cell Therapy for Solid TumorsAnnual Review of Medicine, 2017
- Diagnosis and Management of Ovarian Cancer.2016
- Mesothelin-Targeted CARs: Driving T Cells to Solid TumorsCancer Discovery, 2016
- Apatinib: A promising oral antiangiogenic agent in the treatment of multiple solid tumorsDrugs of Today, 2015
- Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome–positive acute lymphoblastic leukemiaCytotherapy, 2014
- Discovery of Mesothelin and Exploiting It as a Target for ImmunotherapyCancer Research, 2014
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid MalignanciesCancer Immunology Research, 2014
- High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinomaBritish Journal of Cancer, 2009